Aim-quoted Omega, whose remit encompasses testing regarding HIV, food intolerance and allergies as well as infectious diseases, has signed a material transfer agreement (MTA) with Mologic.
The development of the Covid-19 first-generation Elisa (Enzyme Linked Immuno-Sorbent Assay) diagnostics test has been funded in part by the UK government, and it will be able to help identify people that have built up immunity to coronavirus.
Omega has provided Mologic with access to one of its manufacturing facilities (which specialises in manufacturing Elisa tests), in Littleport, Cambridgeshire, and both parties have collaborated to produce pilot batches and first validation batches. Omega said the MTA formalises its access to raw materials and know-how to manufacture Mologic’s diagnostic test at scale.
“Following successful independent validation of Mologic’s Elisa test by the Liverpool School of Tropical Medicine and St George’s, University of London, Mologic has now submitted its test to Public Health England and NHS Scotland for formal validation,” the Scottish firm said”
Omega will also CE Mark the test under the MTA, after which both parties will work together to commercialise it.
The Scottish firm also stressed that the Mologic tie-up is separate from, and additional to, the announcement made by the company on 9 April relating to the UK Rapid Test Consortium, which is to jointly develop and manufacture a point-of-care Covid-19 lateral flow antibody test that could be used at-home, and which will be manufactured in Omega’s Alva facility in Scotland.
Mologic’s Covid-19 Elisa diagnostic test is also an antibody test but will be used on patient samples sent by hospitals or GPs for laboratory testing. There is currently demand for both at-home and laboratory-based tests.
Omega chief executive Colin King said: “We are pleased that Omega has been able to support Mologic with the development and scale up of their Elisa test. This is another example of the UK diagnostics industry working in collaboration to bring effective solutions in the fight against this global pandemic.”Research analysts Mark Brewer and Arshad Ahad at FinnCap said they understand that Omega will sell the test, which could be available within a couple of weeks.
They also estimate that Omega’s production capacity implies potential revenues of £15 million to £30m a year, adding that the global market is set to be for hundreds of millions of tests, potentially.
A message from the Editor:
Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.With the coronavirus lockdown having a major impact on many of our advertisers - and consequently the revenue we receive - we are more reliant than ever on you taking out a digital subscription.Subscribe to scotsman.com and enjoy unlimited access to Scottish news and information online and on our app. With a digital subscription, you can read more than five articles, see fewer ads, enjoy faster load times, and get access to exclusive newsletters and content. Visit www.scotsman.com/subscriptions now to sign up.
Our journalism costs money and we rely on advertising, print and digital revenues to help to support them. By supporting us, we are able to support you in providing trusted, fact-checked content for this website.